What is HC Wainwright's Estimate for KPTI FY2024 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Investment analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst E. White now expects that the company will post earnings of ($1.06) per share for the year, up from their previous forecast of ($1.07). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics' current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics' Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.06) EPS and FY2026 earnings at ($0.53) EPS.

Several other research firms have also issued reports on KPTI. Robert W. Baird decreased their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. StockNews.com lowered shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday. Finally, Piper Sandler upped their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Performance

KPTI traded down $0.01 during trading on Friday, reaching $0.88. The company had a trading volume of 978,610 shares, compared to its average volume of 1,268,307. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company has a market cap of $109.32 million, a price-to-earnings ratio of -0.75 and a beta of 0.16. The firm's 50-day simple moving average is $0.81 and its 200 day simple moving average is $0.91.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million during the quarter, compared to analysts' expectations of $37.86 million. During the same period last year, the business posted ($0.30) earnings per share.

Institutional Trading of Karyopharm Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 DIFC Ltd purchased a new stake in Karyopharm Therapeutics in the second quarter worth approximately $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $143,000. Acadian Asset Management LLC bought a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $167,000. Exchange Traded Concepts LLC lifted its position in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after purchasing an additional 56,613 shares during the last quarter. Finally, Ikarian Capital LLC lifted its position in Karyopharm Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company's stock valued at $618,000 after purchasing an additional 9,355 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).